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Probiotic actions on diseases: implications for
therapeutic treatments
Yi-Heng Chiu,a Shiao-Lin Lin,b Jaw-Ji Tsaic and Meei-Yn Lin*a
The ecology of gut microﬂora, which colonizes all body surfaces, has long coevolved with its hosts in a
complicated fashion. Health beneﬁts conferred by gut microﬂora include defense against invading
pathogens, improvement of nutritional bioavailability, and development of the regional and systemic
immune systems. The past decade has witnessed growing interest in the fact that the gut microﬂora
aﬀects the host's energy homeostasis by means of various mechanisms, including supplying nourishment
from indigestible compounds, producing small biomolecules responsible for lipid proﬁles, and
participating in the absorption, distribution, metabolism and excretion of nutrition. Much in vitro and in
vivo research has indicated that aberrant gut microﬂora plays an important role in the pathogenesis of a
wide spectrum of diseases. This is accomplished by a shift in focus, from laying an emphasis on
pharmacotherapy to placing more eﬀort on gut microﬂora normalization. The objectives of this review
include illustrating trends in the clinical application of probiotics on diseases, as well as discussing
current methodology limitations on probiotic selection. Furthermore, it is expected to shed light on the
nature of probiotics, with the aim of giving greater insight into the implications for clinical use of
probiotics in the treatment of diseases.
Introduction
The human gastrointestinal tract is an ideal residence, which is
full of nutrition, supporting the growth of complicated and
dynamic microora. Our body surfaces that are exposed to the
outer environment are colonized almost everywhere by micro-
ora, especially the skin, respiratory tracts, genitourinary tracts
and gastrointestinal tracts. It is estimated that the gut micro-
ora in humans contains approximately 1014 microbes
(including prokaryotes, protists, parasites, and viruses), ten
times more than the total number of human body cells.1
The composition and function of gut microora have been
demonstrated to be important factors in human health and
diseases.2 Although the denitions of probiotics remain
ambiguous and diverse, the Food and Agriculture Organization
(FAO) and World Health Organization (WHO) research teams
suggest that probiotics are live microorganisms which, when
administered in adequate quantities, confer a health benet
on the host. Taking into account that some literature proposed
that administration of probiotics had no pharmacological
eﬀect on humans, compared with a placebo group,3 the
hypothesis of a host–microbe symbiotic relationship was
addressed elaborately by means of a germ-free animal experi-
ment, which proved that germ-free mice showed reduced
organ weight, reduced cardiac output and reduced immune
functions compared to normal mice.4
To date, there has been a lack of concrete characterization of
the “healthy gut microora” conditions, whether in human
beings or other organisms. However, accumulating research
has revealed that dysbiosis plays an important role in the
pathogenesis of a wide spectrum of diseases.5 Even though the
probiotic eﬀects on diseases are controversial, probiotics have
in fact been reported to be quite relevant to metabolic diseases,
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infectious diseases, gastrointestinal diseases and gastrointes-
tinal oncological diseases.6
The ecology of human gastrointestinal
microﬂora
Obligate anaerobes dominate the main population of micro-
ora, a number that is roughly two to three times greater than
that of facultative anaerobes and aerobes. Until now, over y
prokaryote phyla have been published. However, the majority of
GI microora can be grouped into merely two phyla: the Bac-
teroidetes and the Firmicutes.7 The phylum Bacteroidetes
comprises the main classes of bacteria, which have Gram-
negative, non-sporeforming, anaerobic, and rod-shaped char-
acterization, for example the most famous bacterial species
Escherichia coli. The phylum Firmicutes comprises two main
classes of Bacilli and Clostridia. A large amount of bacteria
under the two classes is Gram-positive, sporeforming, with low-
GC content of genomic DNA. The Bacilli class includes two
orders: Lactobacillales and Bacillales. Almost all probiotic
products on the market belong to the Lactobacillales order, for
example, lactic acid bacteria. By the way, the Bidobacteriales
order is also a popular target of probiotic products. Neverthe-
less, the order belongs to the Actinobacteria phylum, which is
only present in small proportions of GI microora, but is
enriched in the small intestine and colon.8
The number of microbes in our body varies from area to area.
It is assessed that the number of microbes in human bodies
ranges from 101–103 in the stomach and duodenum, 104–107 in
the jejunum and ileum, 1011–1012 in the colon and 109 CFU per
gram in feces. Furthermore, GI microora composition also
diﬀers between sites. In the small intestine, the Actinobacteria
phylum and the Bacilli class of Firmicutes phylum account for
the majority of the microora, whereas the Bacteroidetes
phylum and the Clostridia class of Firmicutes phylum dominate
the majority in the colon.9
Factors known to be involved in GI microora composition
alteration include acquired habits (e.g. smoking and diet),
maternal colonization (e.g. breast milk and the birth canal),
pathogens, genetic proles, immune system development, and
pharmaceutical therapy.10–12 Even though the GI microora
composition uctuates with so many factors, Eckburg et al.
proposed that alteration in GI microora appears to occur
mainly within classes, orders, genera and species. At the
phylum level, it is relatively stable and conserved between
human individuals.13 This research revealed that even under a
variety of intrinsic and extrinsic pressures, the GI microora
might possess redundant functionalities. As a result, it is diﬃ-
cult to shape what “healthy GI microora” is. On the other
hand, thanks to the functionality redundancy property of GI
microora, our physiological state and metabolic capacity are
not easily inuenced by a single factor.
To date, due to well-developed next-generation sequencing
technology, comparative metagenomic and metaproteomic
investigation of gut microbial communities has gained
substantial understanding. The typical changes in composition
of the gut community in patients with certain disorders and the
functional roles of gut microora are increasingly clear. Ferrer
et al. reported that in the gut of obese subjects, the phylum
Firmicutes was more plentiful out of the total microbiota
(94.6%) in comparison with Bacteroidetes, while the gut of the
lean subjects exhibited a signicant shi toward increasing
amounts of the phylum Bacteroidetes.14 Similar results were also
revealed by Larsen and his colleagues.15 They showed that the
proportions of phylum Firmicutes and class Clostridia were
drastically decreased in the diabetic group. Moreover, the ratios
of Bacteroidetes to Firmicutes and the Bacteroides–Prevotella
group to the C. coccoides–E. rectale group correlated positively
with blood glucose level but not with body-mass index (BMI).
The increased ratios of phylum Bacteroidetes to Firmicutes not
only occur in obese/diabetic individuals, but also in those
suﬀering from GI inammation diseases. In addition to varia-
tion in the ratio of phylum Bacteroidetes to Firmicutes, Wouters
et al. discovered that the intestinal microbial composition of
IBD patients showed a reduced ratio of phylum Firmicutes to
Proteobacteria.16
In summary, recent research has proposed that “healthy GI
microora” is characterized by a high amount of obligate
anaerobes and a low concentration of oxygen, as well as a low
redox potential environment. Dysbiosis of the gut microbiota
has been observed in patients with IBD and metabolic diseases,
but the underlying mechanisms resulting in this imbalance
remain vague. Even though growing evidence has proposed that
“healthy GI microora” might be linked to increased ratio of
phylum Firmicutes to Bacteroidetes, do dietary habits or physi-
ological state contribute more to compositional changes of
microora? In other words, is composition alteration of gut
microora perhaps a consequence of disease-caused changes of
the physiological state rather than a primary event? If it is
correct that the change in microbiota is simply a consequence
of the change in physiological state, why have so many clinical
trials yielded positive results? Still, more complementary
studies are needed to support this point of view.
Several lines of study have reported that human GI micro-
ora coevolves with its host. Although Gill and Guarner per-
formed metagenomics analysis, nding that the GI microora
composition is conserved and remains stable within the
phylum level,17 a prospective therapy, intestinal microbiota
transplantation (IMT), is suggested as one alternative treatment
for Clostridium diﬃcile infection; in this approach indigenous
intestinal microora is transplanted from a healthy donor to
patients.18–20 Controversy hence arises as to whether adminis-
tration of probiotics is able to alter the original host's GI
microora or not. We reviewed four categories of human
diseases proposed to be associated with dysbiosis that have
been clinically treated by probiotics.
Probiotics in treating metabolic
diseases
Obesity is threatening all over the developing and developed
world. Unfortunately, obesity rarely comes by itself. High
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development of adipose tissues gives rise to abnormally
increased secretions of pro-inammatory cytokine tumor
necrosis factor-a (TNFa), interleukin-6 (IL-6), as well as
protein hormone leptin, adiponectin and resistin. All these
increased risk factors are directly proportional to both body
fat deposition and serum lipid concentration. Moreover,
they also play roles in diabetes mellitus, non-alcoholic
steatohepatitis and cardiovascular diseases, such as
atherosclerosis.21–23
The last two decades have seen growing importance
placed on research into two metabolic diseases: hyperlipid-
emia/hypocholesterolemia (Table 1) and diabetes (Table 2).
Although there is an abundance of clinical evidence showing
the excellent cholesterol-lowering capacity as well as the
anti-diabetic properties of probiotics, challenges such as
bacterial strain-dependent properties and adequate admin-
istration dosages need more well-established research to
overcome.
Hyperlipidemia and
hypocholesterolemia
Hepner et al. recruited 54 subjects for studying the cholesterol-
lowering activity of yoghurt fermented by Lactobacillus bulgar-
icus and Streptococcus thermophilus.24 The result showed that
serum cholesterol was dramatically reduced by 5 to 10% aer 1
week of fermented milk consumption. Kiessling et al. assessed
the hypocholesterolemic eﬀect of yoghurt fermented with a
mixed culture of Lactobacillus acidophilus 145 and Bidobacte-
rium longum 913 in 29 females aged 19–56 years old.25 The
ndings indicated long-term supplementation with 300 grams
fermented milk over a period of 21 weeks improved the serum
level of HDL cholesterol and gave rise to a decreased LDL/HDL
cholesterol ratio. Another study done by Hlivak et al. assessed
the eﬀects of long-term orally administered probiotic strain E.
faecium M-74 on lipid proles in humans.26 Their results
revealed that aer 56 weeks of probiotic administration, a
decrease in total cholesterol of 12% was observed, but there was
no signicant impact on HDL and triglycerides. For comparison
of probiotics and conventional yogurts with regard to their
eﬃcacy on lipid proles, a clinical trial was performed among
70 pregnant women, and found both probiotics and conven-
tional yogurts showed similar results in the reduction of serum
total cholesterol, LDL, HDL as well as serum triglyceride (TC)
concentrations.27
In discussions of probiotic clinical use in hyperlipidemia
and hypocholesterolemia diseases, Lactobacillus reuteri
NCIMB 30242 has been emphasized in recent years.84,85 Jones
et al. have pointed out that consumption of yoghurt con-
taining L. reuteri NCIMB 30242 is both eﬀective and safe for
lowering LDL-C, TC, apoB-100 and non-HDL-C in hypercho-
lesterolemic subjects. The eﬃcacy of L. reuteri NCIMB 30242
seems to be superior to traditional probiotic therapy and
akin to that of other cholesterol-lowering ingredients. In
addition, L. reuteri NCIMB 30242 was reported to be capable
of increasing the circulation of 25-hydroxyvitamin D (lower-
than-normal levels of serum 25-hydroxyvitamin D may be a
sign of osteoporosis, cardiovascular disease, diabetes, and
cancer) in a trial of a total of 127 healthy hypercholesterol-
emic adults.86
Diﬀerences of gastrointestinal microbiota between obese
and lean phenotypes were primarily observed in leptin-decient
(ob/ob) mice by Ley et al. (2005), showing that compared to lean
mice, ob/ob animals have a 50% decrease in the abundance of
the Bacteroidetes phylum and a proportional increase in the
abundance of Firmicutes.87 Similar results reported by Turn-
baugh et al. suggested that an increase in the proportion of the
Firmicutes phylum was associated with more microbial genes
responsible for encoding enzymes relevant to carbohydrate
metabolism being detected, whichmight increase the capability
for digesting foods and supplying more energy to the host.88
However, due to a lack of models of germ-free human beings, it
is diﬃcult to reproduce the obese phenotype in ethically
compromised human studies. Although the hypothesis that
obesity alters gut microbial ecology has been reproduced in
clinical studies, a consensus has not been reached on whether
or not gut microbial ecology alters the obese phenotype in
humans.
Even though dysbiosis and obesity are not conrmable as
having a cause–eﬀect relationship, there is an increasing trend
in developing approaches (such as probiotics, prebiotics and
synbiotics) to restructure human gut microora towards an
increased ratio of Firmicutes to Bacteroidetes, the latter of which
has been found overpresent in the intestinal tracts of those
obese individuals. As Kalliomaki et al. revealed in their
prospective follow-up study, obese children had diverse gut
microbiota in comparison with lean ones.89 This diﬀerence may
imply that early diﬀerences in fecal microbiota composition in
children may predict overweight, and thus oﬀer new opportu-
nities for preventive measures in early life weight management
before obesity occurs.
Table 1 Hyperlipidemia/hypocholesterolemia clinical trials evaluating the eﬀect of probiotic therapy
Subjects Probiotics Dose (CFU per day) Duration Ref.
54 Yogurt (L. bulgaricus, S. thermophilus) N/A 12 weeks 24
29 Yogurt (L. acidophilus 145, B. longum 913) 108 to 109 7 weeks 25
43 E. faecium M-74 2  109 6–56 weeks 26
60 L. plantarum CECT 7527/7528/7529 1.2  109 12 weeks 28
70 L. acidophilus LA5, B. animalis BB12 1  107 9 weeks 27
114 L. reuteri NCIMB 30242 5  109 (twice) 6 weeks 84
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Diabetes mellitus
Much evidence in both animal and clinical research has
proposed that oxidative stress is of importance in the progres-
sion of type 1 and type 2 diabetes. Maillard reactions of high-
concentration reducing glucose and protein lead to radical
chain polymerization, and in turn irregular oxidative stress
increases lipid peroxidation, membrane disruption and gene
mutation. All these radical-induced types of damage are
hypothesized in relation to the dysfunction of pancreas b-cells
and the development of insulin resistance.29–31
Ejtahed et al. performed a clinical trial to evaluate the eﬀects
of probiotic supplementation on blood glucose and antioxidant
status in type 2 diabetic patients.32 Each patient consumed 300
grams of probiotic yoghurt fermented by Lactobacillus acid-
ophilus La5 and Bidobacterium lactis Bb12. The nal result
showed that probiotic administration improved patients' fast-
ing blood glucose levels and antioxidant capacity, which are
assessed by the status of erythrocyte superoxide dismutase,
glutathione peroxidase, catalase and serum malondialdehyde.
Because of overgrowth of adipose tissue and excess body
weight, increased inammatory cytokine secretions (especially
IL-6) occur for the most part during the third trimester, thus
leading to elevated insulin resistance in pregnancy. Asemi et al.
investigated whether probiotic yoghurt (L. acidophilus LA5 and
B. animalis BB12) or conventional yoghurt (S. thermophilus and
L. bulgaricus) had a more benecial eﬀect on pregnant women
in terms of serum insulin levels. They found that, contrary to
conventional yogurt, daily intake of probiotic yogurt for 9 weeks
had a more signicant eﬀect on maintaining insulin levels and
might improve insulin resistance in pregnant women.33
Unlike type 2 diabetes, which is caused mostly by obesity,
type 1 diabetes results from the failure of the pancreas
insulin-producing b cells to produce insulin. This type can be
further classied as an immune-mediated disease, and was
referred to as “juvenile diabetes”. A 200-subject PRODIA study
was conducted with the aim of investigating whether or not
probiotic intervention could prevent beta cell autoimmunity in
children at genetic risk of type 1 diabetes.34 In this research,
three beta cell autoantibodies (GAD, IA-2, and IAA) were
selected as markers to detect the occurrence of type 1 dia-
betes. The results showed that only one case was analyzed
positive for IAA at 6 months of age. There was no case that
showed positive at 12 months of age. Yet at 24 months of age,
one case was exhibited positive for GADA and another one for
IA-2A. However, no sample presented as positive for more
than one autoantibody.
Probiotics in treating infectious
diseases
Research on probiotics applied to infectious diseases has been
mounting steadily for a number of decades. Several lines of
evidence have suggested that probiotic agents, as an alternative
form of treatment or prevention of infectious diseases, pose
much fewer side eﬀects than typical medicinal therapies.
Among the clinical studies, oral health, gastrointestinal infec-
tions, respiratory and genitourinary tract infections have
attracted the most attention.37–39 A hypothesis, which proposed
that the enhancement of systemic immune responses by pro-
biotics is an important characteristic of successful defense
against invading pathogens, still remains controversial due to a
lack of direct evidence.
For the application of probiotics to the treatment or
prevention of urogenital and gastrointestinal tract infections, in
addition to outstanding antibacterial capacity, the most essen-
tial characteristic probiotics must have in this respect is
dominant colonization ability, and to maintain the acidity of
the environment at a pH lower than 4.5.40 Since the mecha-
nisms underlying probiotic action on infectious diseases are
supposed to be intensication of epithelial and mucosal
barriers, competition and inhibition of pathogen adhesion and
colonization, criteria for probiotic selection are usually estab-
lished according to these distinctive properties. Table 3
summarizes some probiotic clinical use on infectious diseases.
Hemmerling et al. conducted phase 1 (ref. 41) and phase 2a
(ref. 42) of a study evaluating the colonization eﬃciency, safety,
tolerability, and acceptability of Lactobacillus crispatus CTV-05
in women with bacterial vaginosis. Abad and Safdar published a
systemic review, revealing the feasibility of the application of
lactobacilli bacteria, like L. rhamnosus GR-1 and L. reuteri for
prevention and treatment of recurrent bacterial vaginosis.43
Jeppsson et al. reported numerous clinical trials, which have
suggested that probiotics may decrease the number of oppor-
tunistic pathogenic bacteria and restore an impaired barrier
function, suggesting potential for the prevention of post-
operative infections.44 In terms of gastrointestinal infections,
the eﬀectiveness of the alternative probiotic treatment in
decreasing the duration of acute infectious diarrhea in the
pediatric emergency department was evaluated by Nixon and
his colleagues.45 They revealed that among children, adminis-
tration of L. rhamnosus GG decreased the duration of acute
diarrheal illness presenting with more than 2 days of symp-
toms. Probiotic treatment for infectious diseases not only elicits
potent eﬀects on adults and children, but also on infants, as in
Table 2 Diabetes clinical trials evaluating the eﬀect of probiotic therapy
Subjects Probiotics Dose (CFU per day) Duration Ref.
64 Yogurt (L. acidophilus La5, B. lactis Bb12) 108 to 109 6 weeks 32
120 Probiotic mixture Ecological®Barrier 2.5  109 4–26 weeks 35
70 Yogurt (L. bulgaricus, S. thermophilus) 107 9 weeks 33
45 L. acidophilus NCFM 1  1010 4 weeks 36
200 L. rhamnosus GG/LC705, B. breve Bbi99, P. freudenreichii ssp. Shermani JS 5  109, 2  108, 2  109 6–24 weeks 34
628 | Food Funct., 2014, 5, 625–634 This journal is © The Royal Society of Chemistry 2014
Food & Function Review
the clinical trial reported by Taipale et al.46 A randomized,
double-blind, placebo-controlled study done by their research
team suggested that the infants (1 month-old) receiving
B. animalis subsp. lactis BB-12 were experienced no signicant
impact on the occurrence of gastrointestinal symptoms, but
had a reduced risk of respiratory infections compared to those
of the negative control group.
In summary, much research has supported the idea that
probiotics, especially Lactobacillus spp., is highly promising and
safe as a prophylaxis for infectious diseases, while the eﬀec-
tiveness of Bidobacterium spp. seems to be limited to GI
disorders.
Probiotics in treating gastrointestinal
diseases
The integrity of gastrointestinal microora is demonstrated to
be highly correlated with human health, and their disintegra-
tion gives rise to not only gastrointestinal diseases but also to a
wide range of immune and metabolic diseases.47,48 Until now,
various studies have boosted our knowledge of the mecha-
nisms of probiotic action and the evidence for support of their
use in practice. Probiotic alternative therapy has been sug-
gested as being benecial for the treatment of GI diseases in
recent years because of the role of microbiomes, which
suggests that IBDs result from an overaggressive immune
response to a subset of commensal enteric microbes in
genetically predisposed people. It has been shown that anti-
inammatory responses are mediated by TGF and IL-10
production by epithelial cells and mononuclear cells, thus
suppressing Th1 polarization. Until now, there has been much
literature indicating that some strains of probiotics are capable
of up-regulating anti-inammatory cytokine secretions, both in
vitro and in vivo.49–51
Clinical applications of probiotics to GI diseases include
diarrhea caused by antibiotic use, Clostridium diﬃcile infec-
tions, inammatory bowel diseases (IBD) and irritable bowel
syndrome (IBS).
Inﬂammatory bowel diseases
IBD is a collection of inammatory situations occurring on the
colon and small intestine. Two major types of IBD are Crohn's
disease (CD) and ulcerative colitis (UC). The two diseases share
numerous symptoms. However, the main diﬀerence between
CD and UC is that in CD, the inamed area might occur
throughout the digestive tract, while in UC the inammation is
characteristically located in the colon. Since the exact etiology of
a wide spectrum of pathogenic factors in CD and UC has not yet
been well elucidated, in fact many patients still have a reduced
quality of life even under pharmacological treatment. Table 4
and Table 5 show the recent clinical trials of probiotics therapy
on UC and CD, separately.
Anderson et al. undertook a systematic review of fecal
microbiota transplantation in patients with inammatory
bowel diseases and infectious diarrhea.52 The results showed
that the majority of patients under probiotics treatment expe-
rienced a reduction of symptoms (76%), and disease remission
(63%). Surprisingly, all of the cases of C. diﬃcile infections
were resolved. Jonkers et al. conducted a systematic review,
and concluded that the application of Escherichia coli Nissle
1917 in inactive ulcerative colitis (UC) and VSL#3 probiotics in
active UC is promising and warranted. However limited
evidence is available to support the use of probiotics in
Crohn's disease so far.53
More specically for UC treatment, the probiotic mixture
VSL#3 was suggested to be safe and able to decrease UCDAI
(ulcerative colitis disease activity index) scores in patients. A
total of 144 patients were treated with probiotic mixture VSL#3
at a dose of 3.6  1012 CFU per day. The results showed that
aer 8 weeks of treatment, probiotic mixture VSL#3 improves
rectal bleeding and induces remission in relapsing UC
patients.54 Sood et al. also used probiotic mixture VSL#3 to
treat patients with mild-to-moderately active ulcerative colitis,
and reported that probiotic mixture VSL#3 is safe and eﬀective
in achieving clinical responses and remissions in patients that
were given 3.6  1012 CFU twice daily for 12 weeks.55
While in CD treatment, rare trials used probiotics singly
without pharmacotherapy. Besides, the trial length ranges from
3 months to 2 years, much longer times than those used in
clinical UC treatment. Table 5 lists some recent clinical trials
using probiotics, but most of them yielded disappointing
results.
Overall, the eﬀects of probiotics to improve disease
symptoms appear to be acceptable (but not outstanding).
Although there has been a rapid increase in the number of
publications on probiotic use in clinical therapy, the principle
of bacterial strain selection and adequate dosage recom-
mendation needs more empirical research. Further investi-
gation into the mechanisms underlying probiotic action on
GI diseases can be of enormous value to develop novel
selection criteria that is more eﬀective for specic types of
diseases.
Table 3 Infectious disease clinical trials evaluating the eﬀect of probiotic therapy
Subjects Probiotics Dose (CFU per day) Duration Ref.
12 L. crispatus CTV-05 108 to 109 5 days 41
24 L. crispatus CTV-05 2  109 2 weeks 42
159 Probiotic mixture BIO-THREE 109 7 days 44
129 L. rhamnosus GG 109 to 1010 5 days 45
109 B. animalis subsp. lactis BB-12 5  1010 8 months 46
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Irritable bowel syndrome
IBS is a symptom-based diagnosis characterized by recurrent
abdominal pain and alteration of bowel habits accompanied
with discomfort, atulence, bloating, as well as defecatory
dysfunction.66 The IBS etiology, which is proposed to result
from a dysfunctional interaction between the GI microbiota and
the mucosal immunity system, is partially like IBD. However,
the intensity and distribution of the inammatory process and
location are quite diﬀerent. IBS does not induce severe
inammation, ulcers or other damage to the digestive tract.
Over the past few years, growing evidence has accumulated
showing that small intestinal bacterial overgrowth (SIBO) plays
an imperative role, due to the observation of bacterial quanti-
tative changes in the indigenous ora in IBS patients.67
Furthermore, it has been reported that eradicating SIBO via
antibiotics treatment showed a signicant improvement in the
symptoms of IBS patients. Since the decreasing quantity of
intestinal bacteria via antibiotics is a mainstream therapy for
IBS, it raises the possibility of probiotics being used to help
relieve symptoms.
Yoon et al. conducted a trial investigating whether probiotics
treatments are eﬀective in IBS patients, and could alter the
composition of microora.68 Their ndings showed that aer 4
weeks of treatment IBS symptoms were substantially relieved in
the probiotics group (68.0%) compared to the placebo group
(37.5%). In addition, fecal analysis revealed that B. lactis,
L. rhamnosus and S. thermophilus increased considerably.
Another clinical trial focused on IBS patients with constipation
(especially those with delayed transit) was carried out by
Agrawal and his research team.69 Patients consumed milk fer-
mented by B. lactis DN-173 010, which relieved distension and
accelerated gastrointestinal transit, thus improving con-
stipation symptoms. Table 6 lists some recent studies of pro-
biotic clinical use on IBS patients. Although probiotic screening
criteria for IBS remains vague, antibiotics or probiotics treat-
ment with either appear to be eﬀective for ameliorating the
symptoms of IBS patients.
Clostridium diﬃcile infection
C. diﬃcile infection (CDI) is the principal cause of GI
disorder-derived infectious diarrhea. It has been reported that
C. diﬃcile is an opportunistic pathogen which can be found
in many healthy individuals. In general, both patients
suﬀering from GI disorders and infants with underdeveloped
immune systems have an increased risk of CDI.73 Oral
administration of antibiotics (such as metronidazole and
vancomycin) is the most commonly used method for CDI, but
cases of therapeutic failures are usually reported without
clear reasons.
IMT has become a novel, promising treatment for patients
who have failed standard treatment strategies. IMT involves the
administration of a suspension (yogurt, milk, or saline) of
healthy donors' feces into the CDI patients' intestinal tract, with
the aim of remodelling the homeostasis of the intestinal
microbiota. IMT has not been universally advocated as a stan-
dard CDI therapy in part because of poor documentation of
safety assessments.74 Regardless of these concerns, this
approach has been employed in a growing number of patients
with suboptimal response to standard therapy.
A systematic review conducted by Gough et al. revealed that
in 317 patients treated across 27 case series and reports, the
treatment of IMT resolved 92% of cases.75 Kassam et al. con-
ducted a systematic review and meta-analysis, which also
indicated that IMT holds considerable promise for recurrent
CDI treatment.76 In their investigation, 245 out of 273 CDI
patients (90%) reached clinical resolution, and signicant
adverse eﬀects caused by IMT treatment were uncommon.
Nevertheless, both the systematic studies on IMT pose the
Table 4 Ulcerative colitis clinical trials evaluating the eﬀect of probiotic therapy
Subjects Probiotics Dose (CFU per day) Duration Ref.
40 L. reuteri ATCC 55730 1  1010 8 weeks 56
41 B. breve Yakult 3  109 1 year 57
144 VSL#3 probiotic mixture 3.6  1012 8 weeks 54
147 VSL#3 probiotic mixture 3.6  1012 (twice) 12 weeks 55
120 B. longum 2  109 4 weeks 58
90 E. coli Nissle 1  108 2–8 weeks 59
57 E. coli Nissle 1  1011 12 weeks 60
Table 5 Crohn's disease clinical trials evaluating the eﬀect of probiotic therapy
Subjects Probiotics Dose (CFU per day) Duration Ref.
35 B. longum 2  1011 3–6 months 61
75 L. rhamnosus GG 2  1010 2 years 62
70 L. johnsonii, LA1 1  1010 3 months 63
28 E. coli Nissle 5  1010 1 year 64
11 L. rhamnosus GG 2  109 6 months 65
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same problem. Firstly, most case studies are lacking random-
ized, placebo-controlled experiment design and long-term
follow-up reports; secondly, the route of administration, the
criteria for being a feces donor, and the dose of feces given
have not yet been well-standardized.
Because of the relative paucity of mechanisms illustrated
specically for IMT, there is limited, fragile evidence to develop
optimal protocols of IMT to be a standard part of clinical
therapy, with safety being a particular concern. Although
numerous case studies for IMT therapy showed positive results,
still some challenges must be overcome before this therapeutic
tool can be extensively performed.
Probiotics in treating oncological
diseases
Since the integrity of GI microora is highly essential to human
health and its composition changes with age, some aspects of
its integrity and composition are thought to be greatly relevant
to the carcinogenic processes in the host.77–79 The most
frequently occurring and most well-researched cancers are
colorectal cancer and Helicobacter pylori-dependent gastric
cancer.
According to the Center for Disease Control and Prevention
(USA), colorectal cancer is the third most common carcinoma in
the United States and the second most common diagnosed
cancer in the European Union. Many epidemiological studies
have revealed that dietary factors and GI microora play vital
roles in colorectal carcinogenesis. It attracts overwhelming
interest in the potential protective and preventive role of pro-
biotics. The occurrence of cancer begins with accumulative cell
mutations and develops over many years in a multistep and
complicated process. Due to the complexity of colorectal cancer
initiation, promotion and progression, as well as exposure to
diﬀerent carcinogens in the gut, solutions to a single carcino-
genic factor could not exert a signicant eﬀect on such multi-
faceted diseases. So far there has been lack of studies showing
probiotic interventional treatment to be clinically eﬀective on
colorectal cancer patients, even though both in vitro and in vivo
evidence supports the potential anticarcinogenic action of
probiotics.
Helicobacter pylori is a Gram-negative, microaerophilic
bacterium. It has been found in patients suﬀering from chronic
gastritis and gastric ulcers, two diseases which were demon-
strated relative to the development of stomach cancer.80 Indi-
viduals infected with H. pylori have been reported as a risk
factor and one of the major causes of gastric cancer. Several
lines of study have shown that probiotics are very potent for the
improvement ofH. pylori infection.81However, does elimination
ofH. pylori infection reduce the occurrence of gastric cancer? To
date, empirical evidence for gastric cancer prevention by the
elimination of H. pylori is still lacking. The results of meta-
analysis on the correlation between gastric cancer prevention
and H. pylori eradication remain inconsistent and it is hard to
make denitive statements.
Future perspectives on probiotics
Rapidly growing studies on the characteristics of GI microora
in human health and disease have been particularly inuential
in contributing insight into the therapeutic use of probiotics
under specic diseases. In addition to GI diseases, which were
conventionally thought to be highly associated with probiotics,
there is increasing knowledge pointing to the fact that aberrant
GI microora leads a wide range of diseases. In the last decade,
many advances have been made in the area of GI microora-
related diseases, with important perspectives towards docu-
mentation of the specic probiotic strains improving various
aspects of a host's metabolic capacity, and physiological, or
even psychological state.
Until now, clinical use of probiotics has posed several
challenges and problems: Firstly, is vegetative bacteria in fer-
mented milk or lyophilized resting bacteria in capsules the
best approach to probiotic delivery? Although lyophilized
probiotics have low-caloric, portable advantages, and a long
shelf-time, the process of lyophilization could lead to meta-
bolic injury to probiotics, and thus alter their colonization
abilities which are coupled with nutritional requirements.
Also, the lyophilized probiotics need more than half a day to
reach the log phase, the required growth time being much
longer than that of vegetative probiotics. Furthermore,
research teams seldom perform acid-bile resistance tests and
inhibition zone assays using lyophilized resting probiotics.
Whether lyophilized resting (non-spore forming) bacteria or
vegetative bacteria exhibit greater tolerance to acid-bile adver-
sity warrants future investigation.
In terms of probiotic application in metabolic diseases,
Massey (2001) suggested that adequate consumption of
calcium, potassium and magnesium, the three minerals found
in large amounts inmilk or its products (e.g. yogurt and cheese),
at least in part improves hyperglycemia, hyperlipidemia and
hypertension.90 Furthermore, serum levels of magnesium were
inversely correlated with fasting serum insulin, plasma HDL
cholesterol, systolic and diastolic blood pressure. It is worth
Table 6 Irritable bowel syndrome clinical trials evaluating the eﬀect of probiotic therapy
Subjects Probiotics Dose (CFU per day) Duration Ref.
49 LacClean Gold-S® probiotic mixture 5  109 4 weeks 68
214 L. plantarum 299v 1  1011 4 weeks 70
16 L. plantarum MF 1298 1  1010 3 weeks 71
120 E. coli Nissle 2.5–25  109 12 weeks 72
41 Yogurt (Bidobacterium lactis DN-173 010) 1.25  1010 27 days 69
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noting that dairy foods contribute up to sixteen percent of the
daily intake of magnesium in the food supply. Another view-
point reported by Ranadheera et al., proposed that it seems
likely that the probiotic carriers (e.g.milk, cheese and ice cream)
exert a considerable protective eﬀect during the digestion
process, due to the observation that some probiotic culture
starters are sensitive to the gastrointestinal condition, but
usually exist in high quantities in feces.91 For that reason,
evaluation of gastrointestinal tolerance in vitro is not a satis-
factory model predicting in vivo survivability of probiotics
accompanied by the food matrix.
Secondly, what is an appropriate dosage and what is their
duration of use in the body? Over the past years of clinical
trials on diﬀerent diseases, there has been a lack of stan-
dardized or conclusive dosage indication. In addition to the a
recommended dosage, the exact time interval of probiotic
uptake is also a rough question which varies from case to case.
Gill and Guarner suggested daily consumption is probably the
best manner to maintain probiotic eﬀective amounts.82 Har-
vard Women's Health Watch suggested probiotic uptake that
ranges from1 billion to 10 billion colony-forming units for two
to several days per week is enough to achieve eﬃciency.
Another tricky problem of clinical applications is concerned
with probiotic retention time in human bodies. Although the
ability to adhere to human epithelial cells is an important
criterion for probiotics selection, Bezkorovainy reported that
the majority of probiotic adherence to the gut, in general, is
transient and does not permanently colonize as a new member
of the indigenous microora.83 However, it is believed the
probiotics tend to exert their functions and benets when they
proliferate, metabolize and react with host's cells during their
passage through the GI tract.
Thirdly, assessing the presence of fecal probiotic bacteria
aer oral administration was not adequate to predict the pro-
biotic functionality. The currently available method is to
measure the fecal gene content or the colony-forming units of
lactic acid bacteria. Supposing the prerequisite that most pro-
biotics do not permanently colonize in the gut is satised, it is
reasonable to assume that the quantity of fecal probiotics,
which were orally administrated, has an inverse correlation with
the strength of their adherence ability. Such assumption faces
technical limitations because until now there has been lack of
fundamental procedures for detecting the extent of probiotic
proliferation in the gut.
A number of human studies have shown the results of
probiotic clinical use as to the positive, at least in part, eﬀect
on improving the undesirable symptoms of numerous
diseases. Despite the fact that there is encouraging evidence
that particular strains of probiotics are both generally recog-
nized as safe (GRAS) and able to elicit certain functional
benets on humans, the functionality of other strains cannot
be deduced from such specic consequences without empir-
ical evidence. However, in addition to documentation of
specic strains, future research is required to establish a
dosage recommendation and a minimum daily amount
required to exert functional benets, in laying the groundwork
for clinical use.
Database
This systematic review was conducted using Cochrane Database
of Systematic Reviews (CDSR) and Database of Abstracts of
Reviews of Eﬀect (DARE). We searched the human controlled
trials comparing probiotic application on diﬀerent diseases
within ten years.
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